Half of Adverum pipeline 'snaps out of existence' as adverse events force pivot...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 23, 2021 at 11:32 AM.

  1. #1 cafead, Jul 23, 2021 at 11:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via And just like that, half of Adverum Biotechnologies' pipeline is gone.

    The biotech announced after market Thursday that it would abandon a key eye disease indication and shift focus to another, but analysts aren't sure how the company will overcome the adverse events that sent them in the new, slimmed-down direction.

    Adverum will no longer advance the gene therapy ADVM-022 in diabetic macular edema (DME) because of a dose-limiting toxicity, meaning the dose can not be escalated due to side effects. The biotech is forging ahead in wet age-related macular degeneration (wet AMD) but analysts have low expectations for the program.

    article source
     
    Quote

Reply to Thread